Vaderis Therapeutics
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia
$152MSeries B
Role not disclosedPA
Perceptive Advisors
Activity from announced rounds
Activity in this selectionAug 31, 2026 · Aug 1, 2026
Perceptive Advisors is the healthcare investment manager named in Superluminal’s financing and retained company records.
Recorded funding activity
Superluminal develops small-molecule medicines using structural and experimental methods. Vaderis develops an oral treatment for hereditary hemorrhagic telangiectasia, while Imperative develops thromboembolic interventions. The manager remains separate from the Xontogeny venture arm.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $152M 1 disclosed · full round size, not this investor’s share